Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
News Oct 08, 2008
Calando Pharmaceuticals, Inc. has the issuance of U.S. Patent No. 7,427,605, entitled, “Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.”
The patent contains claims directed to inhibitory nucleic acid sequences targeting the Ribonucleotide Reductase Subunit 2 (R2) gene, as well as pharmaceutical compositions and methods for inhibiting tumor growth utilizing the sequences.
R2 is the gene targeted by Calando’s lead siRNA-containing nanoparticle therapeutic, CALAA-01, which is currently in a Phase I clinical trial for patients with non-resectable or metastatic solid tumors. CALAA-01 is the only RNAi therapeutic for cancer to have reached the clinic.
“The issuance of this patent is an important milestone for Calando,” said Dr. Jeremy Heidel, Ph.D., Calando’s Chief Scientific Officer for Nucleic Acid Delivery. “It provides a significant addition to the strong patent portfolio that Calando maintains for its CALAA-01 product.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE